ClinicalTrials.gg
CompletedNCT02999178INBUILD®Updated May 5, 2020Results posted

Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

A Phase 3 interventional study of Nintedanib and Placebo in Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim. Completed at 153 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-05.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
663
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing nintedanib in Lung Diseases, Interstitial — 1 open to participants now, 1 under way, 1 of them phase 3. nintedanib · Lung Diseases, Interstitial.

Enrollment
Largest of 11
663 · median 81
Started
2017
with 1 other
Phase 3
8 of 11
1 open now
Registered
1st of 11
by date
Lead sponsor
6 of 11
Boehringer Ingelheim

Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, this one has the largest enrollment, is one of 2 that started in 2017, is one of 8 in phase 3, and was the 1st registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

1 of the 11 studies testing nintedanib in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing nintedanib in Lung Diseases, Interstitial, or all of them as a file.
02

Study summary

The aim of the current study is to investigate the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) defined as patients who present with features of diffuse fibrosing lung disease of >10% extent on high-resolution computed tomography (HRCT) and whose lung function and respiratory symptoms or chest imaging have worsened despite treatment with unapproved medications used in clinical practice to treat ILD. There is currently no efficacious treatment available for PF-ILD. Based on its efficacy and safety in Idiopathic Pulmonary Fibrosis (IPF), it is anticipated that Nintedanib will be a new treatment option for patients with PF-ILD.

03

Conditions studied

  • Lung Diseases, Interstitial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consistent with International Conference on Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice (ICH-GCP) and local laws signed prior to entry into the study (and prior to any study procedure including shipment of High Resolution Computer Tomography (HRCT) to reviewer).
  • Male or female patients aged >= 18 years at Visit 1.
  • Patients with physician diagnosed Interstitial Lung Disease (ILD) who fulfil at least one of the following criteria for Progressive Fibrosing Interstitial Lung Disease (PF-ILD) within 24 months of screening visit (Visit 1) despite treatment with unapproved medications used in clinical practice to treat ILD, as assessed by the investigator (refer to Exclusion Criteria):

    • decline in Forced Vital Capacity (FVC) % pred based on a relative decline of >=10%
    • Marginal decline in FVC % pred based on a relative decline of .>=5-\<10% combined with worsening of respiratory symptoms
    • Marginal decline in FVC % pred based on a relative decline of >=5-\<10% combined with increasing extent of fibrotic changes on chest imaging
    • Worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging [Note: Changes attributable to comorbidities e.g. infection, heart failure must be excluded. Unapproved medications used in the clinical practice to treat ILD include but are not limited to , azathioprine, mycophenolate mofetil (MMF), n-acetylcysteine (NAC), rituximab, cyclophosphamide, cyclosporine, tacrolimus].
  • Fibrosing lung disease on HRCT, defined as reticular abnormality with traction bronchiectasis with or without honeycombing, with disease extent of >10%, performed within 12 months of Visit 1 as confirmed by central readers.
  • For patients with underlying Connective Tissue Disease (CTD): stable CTD as defined by no initiation of new therapy or withdrawal of therapy for CTD within 6 weeks prior to Visit 1.
  • Carbon Monoxide Diffusion Capacity (DLCO) corrected for (Hb) [visit 1] ≥ 30% and \<80% predicted of normal at Visit 2
  • FVC >= 45% predicted at Visit 2

Exclusion criteria

Exclusion criteria:

  • (AST), Alanine Aminotransferase (ALT) > 1.5 x (ULN) at Visit 1
  • > 1.5 x ULN at Visit 1
  • \<30 mL/min calculated by Cockcroft-Gault formula at Visit 1 [Note: Laboratory parameters from Visit 1 have to satisfy the laboratory threshold values as shown above. Visit 2 laboratory results will be available only after randomization. In case at Visit 2 the results do no longer satisfy the entry criteria, the Investigator has to decide whether it is justified that the patient remains on study drug. The justification for decision needs to be documented. Laboratory parameters that are found to be abnormal at Visit 1 are allowed to be re-tested (once) if it is thought to be a measurement error (i.e. there was no abnormal result of this test in the recent history of the patient and there is no related clinical sign) or the result of a temporary and reversible medical condition, once that condition is resolved].
  • Patients with underlying chronic liver disease ( A, B or C hepatic impairment).
  • Previous treatment with nintedanib or pirfenidone.
  • Other therapy received within 1 month or 6 half-lives (whichever was greater) prior to screening visit (Visit 1).
  • Use of any of the following medications for the treatment of Interstitial Lung Disease (ILD): azathioprine (AZA), cyclosporine, MMF, tacrolimus, oral (OCS) >20mg/day and the combination of OCS+AZA+NAC within 4 weeks of Visit 2, cyclophosphamide within 8 weeks of Visit 2, rituximab within 6 months of Visit 2.

Note: Patients whose Rheumatoid Arthritis (RA)/Connective Tissue Disease (CTD) is managed by these medications should not be considered for participation in the current study unless change in RA/CTD medication is medically indicated (see Inclusion Criteria)

  • Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) based on American Thoracic Society (ATS)/ European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) 2011 Guidelines.
  • Significant Pulmonary Arterial Hypertension (PAH) defined by any of the following:

    • Previous clinical or echocardiographic evidence of significant right heart failure
    • History of right heart catheterization showing a cardiac index \<= 2 l/min/m²
    • PAH requiring parenteral therapy with epoprostenol/treprostinil
    • Primary obstructive airway physiology (pre-bronchodilator /FVC \< 0.7 at Visit 1).
    • In the opinion of the Investigator, other pulmonary abnormalities.
  • Major extrapulmonary physiological restriction (e.g. chest wall abnormality, large pleural effusion)
  • Cardiovascular diseases, any of the following:

    • Severe hypertension, uncontrolled under treatment (≥160/100 mmHg), within 6 month of Visit 1
    • Myocardial infarction within 6 months of Visit 1
    • Unstable cardiac angina within 6 months of Visit 1
  • Bleeding risk, any of the following:

    • Known genetic predisposition to bleeding.
    • Patients who require

      • Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin)
      • High dose antiplatelet therapy. [Note: Prophylactic low dose heparin or heparin flush as needed for maintenance of an indwelling intravenous device (e.g. enoxaparin 4000 I.U. s.c. per day), as well as prophylactic use of antiplatelet therapy (e.g. acetyl salicylic acid up to 325 mg/day, or clopidogrel at 75 mg/day, or equivalent doses of other antiplatelet therapy) are not prohibited].
    • History of haemorrhagic central nervous system (CNS) event within 12 months of Visit 1.
    • Any of the following within 3 months of Visit 1:

      • Haemoptysis or haematuria
      • Active gastro-intestinal (GI) bleeding or GI - ulcers
      • Major injury or surgery (Investigators judgment).
    • Coagulation parameters: (INR) >2, prolongation of prothrombin time (PT) and activated partial thromboplastin time (aPTT) by >1.5 x ULN at Visit 1.
  • History of thrombotic event (including stroke and ) within 12 months of Visit 1.
  • Known to the trial medication or its components (i.e. soya lecithin)
  • Patients with peanut allergy.
  • Other disease that may interfere with testing procedures or in the judgment of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial.
  • for disease other than ILD \< 2.5 years (Investigator assessment).
  • Planned major surgical procedures.
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
  • Women of * not willing or able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly as well as one barrier method for 28 days prior to and 3 months after nintedanib administration. A list of contraception methods meeting these criteria is provided in the patient information.
  • In the opinion of the Investigator, active alcohol or drug abuse.
  • Patients not able to understand or follow trial procedures including completion of self-administered questionnaires without help. *A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
663 participants (actual)

Study arms

  • Experimental
    Nintedanib

    Drug: Nintedanib

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Annual Rate of Decline in Forced Vital Capacity - Overall Population

    Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Overall population consists of all randomized participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only or HRCT fibrotic pattern= Other fibrotic patterns. Annual rate of decline in Forced Vital Capacity in milliliter (mL) per year in the overall population is based on a random coefficient regression with fixed effects for treatment, HRCT fibrotic pattern, and baseline FVC \[mL\], and including treatment-by-time and baseline-by-time interactions. Within-participant errors are modelled by an unstructured variance-covariance matrix.

    Time frame: Baseline, 2, 4, 6, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

  2. Annual Rate of Decline in Forced Vital Capacity - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Annual rate of decline in Forced Vital Capacity in milliliter (mL) per year in participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only is based on a random coefficient regression with fixed effects for treatment, baseline FVC \[mL\], and including treatment-by-time and baseline-by-time interactions. Within-participant errors are modelled by an unstructured variance-covariance matrix.

    Time frame: Baseline, 2, 4, 6, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

Secondary outcomes

  1. Absolute Change From Baseline in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) Total Score at Week 52 - Overall Population

    King's Brief Interstitial Lung Disease questionnaire (K-BILD) consists of 15 items and 3 domains: breathlessness and activities, psychological, and chest symptoms. Possible score ranges from 0-100, score of 100 representing the best health status. If missing items were \>50% per domain, the domain score was set to missing. If any of the domain scores were missing, the total score was set to missing. Absolute change from baseline in K-BILD Total score at week 52 in the overall population was based on a Mixed Model Repeated Measures (MMRM), with fixed effects for baseline K-BILD Total score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline-by-visit interactions and random effect for participant. Visit was the repeated measure. Within-participant errors were modelled by unstructured variance-covariance matrix.

    Time frame: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

  2. Absolute Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    King's Brief Interstitial Lung Disease questionnaire (K-BILD) consists of 15 items and 3 domains: breathlessness and activities, psychological, and chest symptoms. Possible score ranges from 0-100, score of 100 representing the best health status. If missing items were \>50% per domain, the domain score was set to missing. If any of the domain scores were missing, the total score was set to missing. Absolute change from baseline in K-BILD Total score at week 52 in participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only was based on a Mixed Model Repeated Measures (MMRM), with fixed effects for baseline K-BILD Total score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline-by-visit interactions and random effect for participant. Visit was the repeated measure. Within-participant errors were modelled by unstructured variance-covariance matrix.

    Time frame: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

  3. Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Overall Population

    Time to first acute ILD exacerbation or death over 52 weeks was defined as time to first acute ILD exacerbation or death due to any cause within the first 52 weeks and was computed as earliest of date of first documented acute ILD exacerbation or death - date of first drug intake + 1. Participants alive who did not experience any ILD exacerbation event or with unknown status within the first 52 weeks were censored.

    Time frame: From first drug intake until date of first acute ILD exacerbation or date of death or last contact date, up to 372 days

  4. Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    Time to first acute ILD exacerbation or death over 52 weeks was defined as time to first acute ILD exacerbation or death due to any cause within the first 52 weeks and was computed as earliest of date of first documented acute ILD exacerbation or death - date of first drug intake + 1. Participants alive who did not experience any ILD exacerbation event or with unknown status within the first 52 weeks were censored.

    Time frame: From first drug intake until date of first acute ILD exacerbation or date of death or last contact date, up to 372 days

  5. Time to Death Over 52 Weeks - Overall Population

    Time to death over 52 weeks defined as the time from date of first drug intake until date of death from any cause for participants with known date of death (from any cause) within the first 52 weeks. Participants with no event (death from any cause) or unknown status within the first 52 weeks were censored.

    Time frame: From first drug intake until date of death or last contact date, up to 372 days

  6. Time to Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    Time to death over 52 weeks defined as the time from date of first drug intake until date of death from any cause for participants with known date of death (from any cause) within the first 52 weeks. Participants with no event (death from any cause) or unknown status within the first 52 weeks were censored.

    Time frame: From first drug intake until date of death or last contact date, up to 372 days

  7. Time to Death Due to Respiratory Cause Over 52 Weeks - Overall Population

    Time to death due to respiratory cause over 52 weeks is defined as the time from date of first drug intake until date of death attributed to respiratory causes (determined by an independent Adjudication Committee) for participants with known date of death (from respiratory causes) within the first 52 weeks. Participants with no event (death from respiratory causes) or unknown status within the first 52 weeks were censored. As less than 4.95% of the total of participants in the analysis population experienced an event, only descriptive statistics were performed, as pre-specified.

    Time frame: From date of first trial drug intake up to date of death from respiratory causes or last contact date, up to 372 days

  8. Time to Death Due to Respiratory Cause Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    Time to death due to respiratory cause over 52 weeks is defined as the time from date of first drug intake until date of death attributed to respiratory causes (determined by an independent Adjudication Committee) for participants with known date of death (from respiratory causes) within the first 52 weeks. Participants with no event (death from respiratory causes) or unknown status within the first 52 weeks were censored. As less than 4.95% of the total of participants in the analysis population experienced an event, only descriptive statistics were performed, as pre-specified.

    Time frame: From date of first trial drug intake up to date of death from respiratory causes or last contact date, up to 372 days

  9. Time to Progression or Death Over 52 Weeks - Overall Population

    Time to progression or death over 52 weeks is defined as the time from date of first drug intake to date of progression, or date of death (from any cause) if a participant died earlier. Participants with no event (progression or death from any cause) or unknown status were censored. Date of progression is defined as the date when ≥ 10% of absolute decline in FVC percent predicted compared to baseline occured for the first time. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent.

    Time frame: From first drug intake until date of progression or date of death or last contact date, up to 372 days

  10. Time to Progression or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    Time to progression or death over 52 weeks is defined as the time from date of first drug intake to date of progression, or date of death (from any cause) if a participant died earlier. Participants with no event (progression or death from any cause) or unknown status were censored. Date of progression is defined as the date when ≥ 10% of absolute decline in FVC percent predicted compared to baseline occured for the first time. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent.

    Time frame: From first drug intake until date of progression or date of death or last contact date, up to 372 days

  11. Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Overall Population

    Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 10% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 10% and those participants with missing data (worst case analysis).

    Time frame: Baseline and up to 52 weeks after first drug intake

  12. Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 10% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 10% and those participants with missing data (worst case analysis).

    Time frame: Baseline and up to 52 weeks after first drug intake

  13. Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Overall Population

    Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 5% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 5% and those participants with missing data (worst case analysis).

    Time frame: Baseline and up to 52 weeks after first drug intake

  14. Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 5% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 5% and those participants with missing data (worst case analysis).

    Time frame: Baseline and up to 52 weeks after first drug intake

  15. Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52 - Overall Population

    Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms dyspnea domain score (dyspnea score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in dyspnea score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline dyspnea score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline dyspnea score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52).

    Time frame: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

  16. Absolute Change From Baseline in L-PF Symptoms Dyspnea Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms dyspnea domain score (dyspnea score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in dyspnea score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline dyspnea score, visit, treatment-by-visit interaction, baseline dyspnea score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52).

    Time frame: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

  17. Absolute Change From Baseline in L-PF Symptoms Cough Domain Score at Week 52 - Overall Population

    Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms cough domain score (cough score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in cough score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline cough score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline cough score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52).

    Time frame: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

  18. Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

    Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms cough domain score (cough score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in cough score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline cough score, visit, treatment-by-visit interaction, baseline cough score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52).

    Time frame: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

07

Results

Posted May 5, 2020

Participant flow

Randomized (1:1 ratio), placebo-controlled, double-blind, parallel-group trial comparing nintedanib to placebo over a 52-week treatment period (Part A). Participants continued on blinded, randomized treatment beyond 52 weeks (Part B). Data base lock (DBL) one was on 6-June-2019, DBL two was on 11-September-2019. Overall Study Period=Part A and B.

Participant flow — Overall Study
Milestone150 mg NintedanibPlacebo
Started332331
Completed218231
Not completed114100
Withdrew: Adverse event8562
Withdrew: Protocol violation12
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject2121
Withdrew: Other reason not defined above713

Outcome measures

PrimaryAnnual Rate of Decline in Forced Vital Capacity - Overall Population

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Overall population consists of all randomized participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only or HRCT fibrotic pattern= Other fibrotic patterns. Annual rate of decline in Forced Vital Capacity in milliliter (mL) per year in the overall population is based on a random coefficient regression with fixed effects for treatment, HRCT fibrotic pattern, and baseline FVC \[mL\], and including treatment-by-time and baseline-by-time interactions. Within-participant errors are modelled by an unstructured variance-covariance matrix.

Time frame:
Baseline, 2, 4, 6, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)
Reported as:
Least squares mean · Milliliter per year
Annual Rate of Decline in Forced Vital Capacity - Overall Population
Milliliter per year150 mg NintedanibPlacebo
Annual Rate of Decline in Forced Vital Capacity - Overall Population-80.82 (-110.42 to -51.22)-187.78 (-216.92 to -158.64)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Mixed Models Analysis · p = <.0001 (Treatment comparison of slopes was assessed through the treatment-by-time interaction coefficient. P-value was not adjusted for multiple comparisons.) · Adjusted mean difference: 106.96 · 95% CI 65.42 to 148.50Difference of adjusted annual rates of decline was calculated as Nintedanib - Placebo.
PrimaryAnnual Rate of Decline in Forced Vital Capacity - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Annual rate of decline in Forced Vital Capacity in milliliter (mL) per year in participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only is based on a random coefficient regression with fixed effects for treatment, baseline FVC \[mL\], and including treatment-by-time and baseline-by-time interactions. Within-participant errors are modelled by an unstructured variance-covariance matrix.

Time frame:
Baseline, 2, 4, 6, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)
Reported as:
Least squares mean · Milliliter per year
Annual Rate of Decline in Forced Vital Capacity - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Milliliter per year150 mg NintedanibPlacebo
Annual Rate of Decline in Forced Vital Capacity - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only-82.87 (-123.73 to -42.02)-211.07 (-251.38 to -170.77)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Mixed Models Analysis · p = <.0001 (Treatment comparison of slopes was assessed through the treatment-by-time interaction coefficient. P-value was not adjusted for multiple comparisons.) · Adjusted mean difference: 128.20 · 95% CI 70.81 to 185.59Difference of adjusted annual rates of decline was calculated as Nintedanib - Placebo.
SecondaryAbsolute Change From Baseline in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) Total Score at Week 52 - Overall Population

King's Brief Interstitial Lung Disease questionnaire (K-BILD) consists of 15 items and 3 domains: breathlessness and activities, psychological, and chest symptoms. Possible score ranges from 0-100, score of 100 representing the best health status. If missing items were \>50% per domain, the domain score was set to missing. If any of the domain scores were missing, the total score was set to missing. Absolute change from baseline in K-BILD Total score at week 52 in the overall population was based on a Mixed Model Repeated Measures (MMRM), with fixed effects for baseline K-BILD Total score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline-by-visit interactions and random effect for participant. Visit was the repeated measure. Within-participant errors were modelled by unstructured variance-covariance matrix.

Time frame:
Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) Total Score at Week 52 - Overall Population
Unit on scale150 mg NintedanibPlacebo
Absolute Change From Baseline in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) Total Score at Week 52 - Overall Population0.55 (-0.62 to 1.72)-0.79 (-1.94 to 0.37)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Mixed Model Repeated Measures (MMRM) · p = 0.1115 · Adjusted mean difference: 1.34 · 95% CI -0.31 to 2.98Adjusted mean difference was calculated as Nintedanib - Placebo.
SecondaryAbsolute Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

King's Brief Interstitial Lung Disease questionnaire (K-BILD) consists of 15 items and 3 domains: breathlessness and activities, psychological, and chest symptoms. Possible score ranges from 0-100, score of 100 representing the best health status. If missing items were \>50% per domain, the domain score was set to missing. If any of the domain scores were missing, the total score was set to missing. Absolute change from baseline in K-BILD Total score at week 52 in participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only was based on a Mixed Model Repeated Measures (MMRM), with fixed effects for baseline K-BILD Total score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline-by-visit interactions and random effect for participant. Visit was the repeated measure. Within-participant errors were modelled by unstructured variance-covariance matrix.

Time frame:
Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Unit on scale150 mg NintedanibPlacebo
Absolute Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only0.75 (-0.82 to 2.31)-0.78 (-2.34 to 0.78)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Mixed Model Repeated Measures (MMRM) · p = 0.1747 · Adjusted mean difference: 1.53 · 95% CI -0.68 to 3.74Adjusted mean difference was calculated as Nintedanib - Placebo.
SecondaryTime to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Overall Population

Time to first acute ILD exacerbation or death over 52 weeks was defined as time to first acute ILD exacerbation or death due to any cause within the first 52 weeks and was computed as earliest of date of first documented acute ILD exacerbation or death - date of first drug intake + 1. Participants alive who did not experience any ILD exacerbation event or with unknown status within the first 52 weeks were censored.

Time frame:
From first drug intake until date of first acute ILD exacerbation or date of death or last contact date, up to 372 days
Reported as:
Median · Days
Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Overall Population
Days150 mg NintedanibPlacebo
Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Overall PopulationNA (NA to NA)NA (NA to NA)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Log Rank · p = 0.3948 · Hazard ratio (hr): 0.80 · 95% CI 0.48 to 1.34A Cox proportional hazards model, stratified by HRCT fibrotic pattern, was used to estimate the hazard ratio calculated as Nintedanib divided by Placebo.
SecondaryTime to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Time to first acute ILD exacerbation or death over 52 weeks was defined as time to first acute ILD exacerbation or death due to any cause within the first 52 weeks and was computed as earliest of date of first documented acute ILD exacerbation or death - date of first drug intake + 1. Participants alive who did not experience any ILD exacerbation event or with unknown status within the first 52 weeks were censored.

Time frame:
From first drug intake until date of first acute ILD exacerbation or date of death or last contact date, up to 372 days
Reported as:
Median · Days
Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Days150 mg NintedanibPlacebo
Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern OnlyNA (NA to NA)NA (NA to NA)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Log Rank · p = 0.1985 · Hazard ratio (hr): 0.67 · 95% CI 0.36 to 1.24A Cox proportional hazards model was used to estimate the hazard ratio calculated as Nintedanib divided by Placebo.
SecondaryTime to Death Over 52 Weeks - Overall Population

Time to death over 52 weeks defined as the time from date of first drug intake until date of death from any cause for participants with known date of death (from any cause) within the first 52 weeks. Participants with no event (death from any cause) or unknown status within the first 52 weeks were censored.

Time frame:
From first drug intake until date of death or last contact date, up to 372 days
Reported as:
Median · Days
Time to Death Over 52 Weeks - Overall Population
Days150 mg NintedanibPlacebo
Time to Death Over 52 Weeks - Overall PopulationNA (NA to NA)NA (NA to NA)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Log Rank · p = 0.8544 · Hazard ratio (hr): 0.94 · 95% CI 0.47 to 1.86A Cox proportional hazards model, stratified by HRCT fibrotic pattern, was used to estimate the hazard ratio calculated as Nintedanib divided by Placebo.
SecondaryTime to Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Time to death over 52 weeks defined as the time from date of first drug intake until date of death from any cause for participants with known date of death (from any cause) within the first 52 weeks. Participants with no event (death from any cause) or unknown status within the first 52 weeks were censored.

Time frame:
From first drug intake until date of death or last contact date, up to 372 days
Reported as:
Median · Days
Time to Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Days150 mg NintedanibPlacebo
Time to Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern OnlyNA (NA to NA)NA (NA to NA)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Log Rank · p = 0.3291 · Hazard ratio (hr): 0.68 · 95% CI 0.32 to 1.47A Cox proportional hazards model was used to estimate the hazard ratio calculated as Nintedanib divided by Placebo.
SecondaryTime to Death Due to Respiratory Cause Over 52 Weeks - Overall Population

Time to death due to respiratory cause over 52 weeks is defined as the time from date of first drug intake until date of death attributed to respiratory causes (determined by an independent Adjudication Committee) for participants with known date of death (from respiratory causes) within the first 52 weeks. Participants with no event (death from respiratory causes) or unknown status within the first 52 weeks were censored. As less than 4.95% of the total of participants in the analysis population experienced an event, only descriptive statistics were performed, as pre-specified.

Time frame:
From date of first trial drug intake up to date of death from respiratory causes or last contact date, up to 372 days
Reported as:
Median · Days
Time to Death Due to Respiratory Cause Over 52 Weeks - Overall Population
Days150 mg NintedanibPlacebo
Time to Death Due to Respiratory Cause Over 52 Weeks - Overall PopulationNA (NA to NA)NA (NA to NA)
SecondaryTime to Death Due to Respiratory Cause Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Time to death due to respiratory cause over 52 weeks is defined as the time from date of first drug intake until date of death attributed to respiratory causes (determined by an independent Adjudication Committee) for participants with known date of death (from respiratory causes) within the first 52 weeks. Participants with no event (death from respiratory causes) or unknown status within the first 52 weeks were censored. As less than 4.95% of the total of participants in the analysis population experienced an event, only descriptive statistics were performed, as pre-specified.

Time frame:
From date of first trial drug intake up to date of death from respiratory causes or last contact date, up to 372 days
Reported as:
Median · Days
Time to Death Due to Respiratory Cause Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Days150 mg NintedanibPlacebo
Time to Death Due to Respiratory Cause Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern OnlyNA (NA to NA)NA (NA to NA)
SecondaryTime to Progression or Death Over 52 Weeks - Overall Population

Time to progression or death over 52 weeks is defined as the time from date of first drug intake to date of progression, or date of death (from any cause) if a participant died earlier. Participants with no event (progression or death from any cause) or unknown status were censored. Date of progression is defined as the date when ≥ 10% of absolute decline in FVC percent predicted compared to baseline occured for the first time. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent.

Time frame:
From first drug intake until date of progression or date of death or last contact date, up to 372 days
Reported as:
Median · Days
Time to Progression or Death Over 52 Weeks - Overall Population
Days150 mg NintedanibPlacebo
Time to Progression or Death Over 52 Weeks - Overall PopulationNA (367 to NA)NA (269 to NA)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Log Rank · p = 0.0017 · Hazard ratio (hr): 0.65 · 95% CI 0.49 to 0.85A Cox proportional hazards model, stratified by HRCT fibrotic pattern, was used to estimate the hazard ratio calculated as Nintedanib divided by Placebo.
SecondaryTime to Progression or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Time to progression or death over 52 weeks is defined as the time from date of first drug intake to date of progression, or date of death (from any cause) if a participant died earlier. Participants with no event (progression or death from any cause) or unknown status were censored. Date of progression is defined as the date when ≥ 10% of absolute decline in FVC percent predicted compared to baseline occured for the first time. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent.

Time frame:
From first drug intake until date of progression or date of death or last contact date, up to 372 days
Reported as:
Median · Days
Time to Progression or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Days150 mg NintedanibPlacebo
Time to Progression or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern OnlyNA (365 to NA)NA (254 to NA)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Log Rank · p = 0.0081 · Hazard ratio (hr): 0.64 · 95% CI 0.45 to 0.89A Cox proportional hazards model was used to estimate the hazard ratio calculated as Nintedanib divided by Placebo.
SecondaryPercentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Overall Population

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 10% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 10% and those participants with missing data (worst case analysis).

Time frame:
Baseline and up to 52 weeks after first drug intake
Reported as:
Number · Percentage of participants
Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Overall Population
Percentage of participants150 mg NintedanibPlacebo
Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Overall Population40.748.9
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Regression, Logistic · Adjusted odds ratio: 0.70 · 95% CI 0.52 to 0.96Ratio calculated as Nintedanib divided by Placebo.
SecondaryPercentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 10% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 10% and those participants with missing data (worst case analysis).

Time frame:
Baseline and up to 52 weeks after first drug intake
Reported as:
Number · Percentage of participants
Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Percentage of participants150 mg NintedanibPlacebo
Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only41.352.4
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Regression, Logistic · Adjusted odds ratio: 0.63 · 95% CI 0.43 to 0.94Ratio calculated as Nintedanib divided by Placebo.
SecondaryPercentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Overall Population

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 5% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 5% and those participants with missing data (worst case analysis).

Time frame:
Baseline and up to 52 weeks after first drug intake
Reported as:
Number · Percentage of participants
Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Overall Population
Percentage of participants150 mg NintedanibPlacebo
Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Overall Population52.468.6
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Regression, Logistic · Adjusted odds ratio: 0.50 · 95% CI 0.36 to 0.68Ratio calculated as Nintedanib divided by Placebo.
SecondaryPercentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 5% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 5% and those participants with missing data (worst case analysis).

Time frame:
Baseline and up to 52 weeks after first drug intake
Reported as:
Number · Percentage of participants
Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Percentage of participants150 mg NintedanibPlacebo
Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only52.470.4
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Regression, Logistic · Adjusted odds ratio: 0.46 · 95% CI 0.31 to 0.69Ratio calculated as Nintedanib divided by Placebo.
SecondaryAbsolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52 - Overall Population

Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms dyspnea domain score (dyspnea score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in dyspnea score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline dyspnea score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline dyspnea score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52).

Time frame:
Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52 - Overall Population
Unit on scale150 mg NintedanibPlacebo
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52 - Overall Population4.28 (2.43 to 6.14)7.81 (5.97 to 9.66)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Mixed Model Repeated Measures · Adjusted mean difference: -3.53 · 95% CI -6.14 to -0.92Adjusted mean difference was calculated as Nintedanib - Placebo.
SecondaryAbsolute Change From Baseline in L-PF Symptoms Dyspnea Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms dyspnea domain score (dyspnea score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in dyspnea score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline dyspnea score, visit, treatment-by-visit interaction, baseline dyspnea score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52).

Time frame:
Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in L-PF Symptoms Dyspnea Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Unit on scale150 mg NintedanibPlacebo
Absolute Change From Baseline in L-PF Symptoms Dyspnea Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only4.14 (1.81 to 6.47)8.32 (5.99 to 10.66)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Mixed Model Repeated Measures · Adjusted mean difference: -4.18 · 95% CI -7.48 to -0.88Adjusted mean difference was calculated as Nintedanib - Placebo.
SecondaryAbsolute Change From Baseline in L-PF Symptoms Cough Domain Score at Week 52 - Overall Population

Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms cough domain score (cough score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in cough score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline cough score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline cough score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52).

Time frame:
Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in L-PF Symptoms Cough Domain Score at Week 52 - Overall Population
Unit on scale150 mg NintedanibPlacebo
Absolute Change From Baseline in L-PF Symptoms Cough Domain Score at Week 52 - Overall Population-1.84 (-4.36 to 0.69)4.25 (1.74 to 6.76)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Mixed Model Repeated Measures · Adjusted mean difference: -6.09 · 95% CI -9.65 to -2.53Adjusted mean difference was calculated as Nintedanib - Placebo.
SecondaryAbsolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms cough domain score (cough score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in cough score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline cough score, visit, treatment-by-visit interaction, baseline cough score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52).

Time frame:
Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
Unit on scale150 mg NintedanibPlacebo
Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only-3.20 (-6.43 to 0.04)4.09 (0.85 to 7.32)
Statistical analysis
  • 150 mg Nintedanib vs Placebo · Mixed Model Repeated Measures · Adjusted mean difference: -7.28 · 95% CI -11.86 to -2.71Adjusted mean difference was calculated as Nintedanib - Placebo.

Adverse events

Collected over Treatment period plus 28 days (residual effect period), up to 836 days. Time frame for All-Cause-Mortality: Treatment period plus Follow-up, up to 900 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib36/332 (10.8%)147/332 (44.3%)308/332 (92.8%)
Placebo45/331 (13.6%)164/331 (49.5%)266/331 (80.4%)
Most frequent serious events
Showing 10 of 240
Most frequent serious events
EventNintedanibPlacebo
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders19/33245/331
PneumoniaInfections and infestations24/33216/331
Acute respiratory failureRespiratory, thoracic and mediastinal disorders16/3327/331
DyspnoeaRespiratory, thoracic and mediastinal disorders6/33213/331
Respiratory failureRespiratory, thoracic and mediastinal disorders11/33210/331
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders5/3329/331
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders7/3325/331
Chronic respiratory failureRespiratory, thoracic and mediastinal disorders1/3326/331
PneumothoraxRespiratory, thoracic and mediastinal disorders6/3326/331
Drug-induced liver injuryHepatobiliary disorders6/3320/331
Most frequent other events
Showing 10 of 30
Most frequent other events
EventNintedanibPlacebo
DiarrhoeaGastrointestinal disorders239/33285/331
NauseaGastrointestinal disorders100/33233/331
VomitingGastrointestinal disorders64/33216/331
BronchitisInfections and infestations44/33262/331
NasopharyngitisInfections and infestations54/33248/331
Decreased appetiteMetabolism and nutrition disorders54/33222/331
CoughRespiratory, thoracic and mediastinal disorders40/33250/331
Weight decreasedInvestigations49/33218/331
DyspnoeaRespiratory, thoracic and mediastinal disorders49/33246/331
Alanine aminotransferase increasedInvestigations47/33212/331

Baseline characteristics

Treated set: This set included all randomized participants who received at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(Years)150 mg NintedanibPlaceboTotal
Mean65.2 ± 9.766.3 ± 9.865.8 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)150 mg NintedanibPlaceboTotal
Female153154307
Male179177356
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)150 mg NintedanibPlaceboTotal
Hispanic or Latino474996
Not Hispanic or Latino285282567
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)150 mg NintedanibPlaceboTotal
American Indian or Alaska Native000
Asian8380163
Native Hawaiian or Other Pacific Islander101
Black or African American5510
White242246488
More than one race101
Unknown or Not Reported000
Baseline High Resolution Computed Tomography (HRCT) fibrotic pattern
Baseline High Resolution Computed Tomography (HRCT) fibrotic pattern(Participants)150 mg NintedanibPlaceboTotal
UIP-like fibrotic pattern only206206412
Other fibrotic patterns126125251
Baseline Forced Vital Capacity (FVC) - Overall Population
Baseline Forced Vital Capacity (FVC) - Overall Population(Milliliter (mL))150 mg NintedanibPlaceboTotal
Mean2340.07 ± 740.192321.15 ± 727.972330.62 ± 733.62
Baseline FVC - Participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only
Baseline FVC - Participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only(Milliliter (mL))150 mg NintedanibPlaceboTotal
Mean2363.43 ± 762.892373.59 ± 720.052368.51 ± 740.89
08

Study locations

153 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Pulmonary and Sleep Specialists
    Danbury, Connecticut 06810, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Pulmonary and Sleep of Tampa Bay
    Brandon, Florida 33511, United States
  • University of Florida College of Medicine
    Jacksonville, Florida 32209, United States
  • University of Miami
    Miami, Florida 33125, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21224, United States
  • Pulmonary and Critical Care Associates of Baltimore
    Towson, Maryland 21286, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Pulmonary and Critical Care Medicine
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Spectrum Health
    Grand Rapids, Michigan 49546, United States
  • University of Minnesota Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic, Rochester
    Rochester, Minnesota 55905, United States
  • The Lung Research Center, LLC
    Chesterfield, Missouri 63017, United States
  • Creighton University
    Omaha, Nebraska 68124, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center-New York Presbyterian Hospital
    New York, New York 10032, United States
  • NewYork-Presbyterian/Weill Cornell Medical Center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • The Oregon Clinic
    Portland, Oregon 97220, United States
  • The Oregon Clinic
    Portland, Oregon 97225, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Temple University Hospital
    Oaks, Pennsylvania 19456, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of South Carolina
    Columbia, South Carolina 29203, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Pul & Crit Care Conslt
    Fort Worth, Texas 76104, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Medical Arts and Research Center (MARC)
    San Antonio, Texas 78229, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84108, United States
  • Inova Fairfax Medical Campus
    Falls Church, Virginia 22042, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23225, United States
  • Centro Dr. Lazaro Langer S.R.L
    Alberdi Sur, X5003DCE, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    C.a.b.a, 1056, Argentina
  • Sanatorio Güemes
    Ciudad Autónoma de Bs As, C1180AAX, Argentina
  • CEMER-Centro Medico De Enfermedades Respiratorias
    Florida, B1602DQD, Argentina
  • INSARES
    Mendoza, M5500CCG, Argentina
  • Instituto Médico de la Fundación Estudios Clínicos
    Rosario, S2000DEJ, Argentina
  • Centre Hospitalier Universitaire de Liège
    Angleur, 4031, Belgium
  • ULB Hopital Erasme
    Bruxelles, 1070, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Yvoir - UNIV UCL de Mont-Godinne
    Yvoir, 5530, Belgium
  • Concordia Hospital
    Winnipeg, Manitoba R2K 3S8, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • CHUS Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • Hospital Clínico Reg. de Concepción "Dr. G. Grant Benavente"
    Concepción, 4070038, Chile
  • Instituto Nacional del Tórax
    Providencia, Santiago De Chile, 7500000, Chile
  • Centro de Investigación del Maule
    Talca, 3465586, Chile
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, 510120, China
  • Nanjing Drum Tower Hospital
    Nanjing, 210008, China
  • The First Hospital of Chinese Medical University
    Shenyang, China
  • HOP Avicenne
    Bobigny, 93009, France
  • HOP Louis Pradel
    Bron, 69500, France
  • HOP Côte de Nacre
    Caen, 14033, France
  • HOP d'Instruction des Armées Percy
    Clamart, 92140, France
  • HOP Calmette
    Lille, 59037, France
  • HOP Nord
    Marseille, 13015, France
  • HOP Arnaud de Villeneuve
    Montpellier, 34295, France
  • HOP Pasteur
    Nice, 06001, France
  • HOP Bichat
    Paris, 75018, France
  • HOP Maison Blanche
    Reims, 51092, France
  • HOP Pontchaillou
    Rennes, 35033, France
  • HOP Civil
    Strasbourg, 67091, France
  • HOP Bretonneau
    Tours, 37000, France
  • Universitätsklinikum Bonn AöR
    Bonn, 53105, Germany
  • Fachkrankenhaus Coswig GmbH
    Coswig, 01640, Germany
  • Klinik Donaustauf
    Donaustauf, 93093, Germany
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
    Essen, 45239, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Wissenschaftliches Institut Bethanien
    Solingen, 42699, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Petrus-Krankenhaus
    Wuppertal, 42283, Germany
  • A.O.U. Policlinico Vittorio Emanuele
    Catania, 95124, Italy
  • Ospedale "G.B. Morgagni - L. Pierantoni" ausl forli
    FORLì, 47121, Italy
  • Azienda Ospedaliera Policlinico di Modena
    Modena, 41100, Italy
  • A.O. San Gerardo di Monza
    Monza, 20900, Italy
  • Policlinico Gemelli
    Roma, 00168, Italy

Showing the first 100 of 153 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ogura T, Suda T, Inase N, Nishioka Y, Azuma A, Okamoto M, Takizawa A, Ito T, Rohr KB, Inoue Y. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial. Respir Investig. 2022 Nov;60(6):787-797. doi: 10.1016/j.resinv.2022.06.009. Epub 2022 Aug 1. PubMed 35927208 ↗
  • Cottin V, Martinez FJ, Jenkins RG, Belperio JA, Kitamura H, Molina-Molina M, Tschoepe I, Coeck C, Lievens D, Costabel U. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respir Res. 2022 Apr 7;23(1):85. doi: 10.1186/s12931-022-01974-2. PubMed 35392908 ↗
  • Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ Open Respir Res. 2022 Mar;9(1):e001167. doi: 10.1136/bmjresp-2021-001167. PubMed 35241434 ↗
  • Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respir Med. 2021 Oct;187:106574. doi: 10.1016/j.rmed.2021.106574. Epub 2021 Aug 12. PubMed 34564020 ↗
  • Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, Walsh SLF, Kolb M, Koschel D, Moua T, Stowasser S, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2022 Mar 17;59(3):2004538. doi: 10.1183/13993003.04538-2020. Print 2022 Mar. PubMed 34475231 ↗
  • Maher TM, Brown KK, Kreuter M, Devaraj A, Walsh SLF, Lancaster LH, Belloli EA, Padilla M, Behr J, Goeldner RG, Tetzlaff K, Schlenker-Herceg R, Flaherty KR; INBUILD trial investigators. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. Eur Respir J. 2022 Feb 3;59(2):2004587. doi: 10.1183/13993003.04587-2020. Print 2022 Feb. PubMed 34210788 ↗
  • Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, Tomassetti S, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R, Kolb M; INBUILD Trial Investigators. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res. 2021 Mar 16;22(1):84. doi: 10.1186/s12931-021-01668-1. PubMed 33726766 ↗
  • Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020 Jun 25;55(6):2000085. doi: 10.1183/13993003.00085-2020. Print 2020 Jun. PubMed 32217654 ↗
  • Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. PubMed 32145830 ↗
  • Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. PubMed 31566307 ↗
  • Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017. PubMed 29018526 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2019, 27 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2016
First posted
Dec 21, 2016
StartActual
Jan 17, 2017
Primary completionActual
Apr 23, 2019
CompletionActual
Aug 12, 2019
Results first posted
May 5, 2020
Last update
May 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02999178
Responsible party
Sponsor
First posted
Dec 21, 2016
Start date
Jan 17, 2017
Primary completion
Apr 23, 2019
Completion
Aug 12, 2019
Results posted
May 5, 2020
Last update
May 5, 2020

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion